Show simple item record

dc.contributor.advisorHelleday, Thomasen
dc.contributor.advisorPuumalainen, Marjo-Riittaen
dc.contributor.advisorVisnes, Torkilden
dc.contributor.advisorJaks, Viljaret
dc.contributor.authorTampere, Marianna
dc.contributor.otherTartu Ülikool. Loodus- ja tehnoloogiateaduskondet
dc.contributor.otherTartu Ülikool. Molekulaar- ja rakubioloogia instituutet
dc.date.accessioned2016-08-10T12:38:39Z
dc.date.available2016-08-10T12:38:39Z
dc.date.issued2016
dc.identifier.urihttp://hdl.handle.net/10062/52932
dc.description.abstractNovel anticancer therapies are needed to overcome drug resistance of chemotherapeutic drugs leading to tumor relapse. Combination therapy with target-specific drugs underlies great potential to increase the efficiency of chemotherapy. Increased DNA repair capacity is one of the resistance mechanism of chemotherapy drug cisplatin. Here, inhibitors against DNA glycosylase OGG1 were studied to overcome cisplatin resistance. Combination treatment of OGG1 inhibitor with cisplatin reduced the proliferation of cisplatin resistant bladder cancer cells, whereas sensitive cells did not respond. Increased OGG1 levels in resistant cells and decreased OGG1-GEP mobility upon cisplatin treatment suggests that OGG1 might support cisplatin resistance. Moreover, the activity of PGG1 upon MTH1 inhibition was studied as a side project as both of these enzymes are responsible for 8-oxoG repair, but the findings did not support a role of OGG1 in mediating DNA repair upon MTH1 inhibition. Overall, this study gives insights how OGG1 inhibition could be exploited in anticancer combination therapy.en
dc.language.isoenen
dc.publisherTartu Ülikoolen
dc.subjectbase excision repairen
dc.subjectcisplatinen
dc.subjectOGG1en
dc.subjectMTH1en
dc.subjectsmall-molecule inhibitorsen
dc.subject.othermagistritöödet
dc.titleOGG1 inhibition as combination treatment for cancer therapyen
dc.typeThesisen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record